- Created on the 11 May, 2017.
Prostate specific antigen (PSA) is a glycoprotein which can be produced by the prostate gland, bulbourethral gland and lining of the urethra. PSA has become a vital marker for prostate carcinoma, it offers better sensitivity and specificity when compared to other biochemical marker such as total alkaline phosphatase, PAP and carcinoembryonic antigen. Usually there is very little PSA which is secreted in the blood, however, increase in tissue damage and glandular size can result in prostate cancer, prostatitis and benign prostatic hypertrophy which can lead to an increase in the levels of circulating PSA.
PSA is found to exist in serum in multiple forms: enveloped by alpha-2-macroglobulin, complexed to alpha-1-anti-chymotrypsin (PSA-ACT complex) and unbound (free PSA). Higher total PSA concentrations and lower percentages of free PSA have been associated with higher risks of prostate cancer. A total PSA range of 4.0-10.0 ng/mL has been identified as a diagnostic “gray zone,” whereby the free:total PSA ratio can be useful in helping to determine the relative risk of prostate cancer. Therefore, many urologists are recommending using the free:total PSA ratio in order to identify which men should undergo biopsy. There is evidence that up to 20% of men that had a negative biopsy result were found to have the cancer. Therefore, regular analysis of PSA is crucial tool in order to examine the actual and potential and effectiveness of surgery and other therapies. The measurement of PSA serum levels is not only vital to screen patients for prostate cancer, but is also important to monitor patients that have been treated for this disease. An increase of the levels of PSA in patients following radiotherapy or radical prostatectomy could allow an earlier discovery of recurrent or residual carcinoma.
Human total PSA ELISA kit is a procedure for analysing in vitro quantitative concentrations of total prostate specific antigen (kallikrein-3, gamma-seminoprotein) in human serum and plasma. This assay has a minimum sensitivity limit of 0.2 ng/ml.
The minimum detection sensitivity level of human total PSA using this human total prostate-specific antigen ELISA kit was 0.2 ng/ml. The dynamic assay range for this kit is 1.56 – 25.0 ng/ml.
- Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl. (1996) 7: 64-9. Review. Catalona W.J.
- Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers. Curr Urol Rep. (2015) 16 (9): 63. Review. Morgan T., et al.
- Early detection of prostate cancer: is PSA a reliable option? Tex Med. (2001) 97 (2): 59-62. Review. Okihara K. and Babaian R.J.
- Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med. (2009) 47 (11): 1325-31. Review. Stephan C., et al.
- Full Name: Total Prostate Specific Antigen (Total PSA) ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma
- Sensitivity: 0.2 ng/ml